- Clinical Trials
- April 2025
- 180 Pages
Global
From €2718EUR$3,000USD£2,343GBP
- Report
- July 2025
- 100 Pages
Global
From €4439EUR$4,900USD£3,826GBP
From €4439EUR$4,900USD£3,826GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2527EUR$2,789USD£2,178GBP
- Report
- June 2025
- 400 Pages
Global
From €4483EUR$4,949USD£3,864GBP
- Report
- May 2024
- 138 Pages
Global
From €5887EUR$6,499USD£5,075GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4484EUR$4,950USD£3,865GBP
- Report
- November 2023
- 432 Pages
Global
From €8606EUR$9,500USD£7,418GBP
- Report
- November 2023
- 230 Pages
Global
From €6794EUR$7,500USD£5,856GBP
- Report
- May 2022
- 84 Pages
Global
From €1812EUR$2,000USD£1,562GBP
The Metastatic Prostate Cancer Drug market is a subset of the larger Prostate Cancer Drugs market. It is composed of drugs used to treat metastatic prostate cancer, which is cancer that has spread beyond the prostate to other parts of the body. These drugs are typically used in combination with other treatments such as surgery, radiation, and hormone therapy. Common drugs used to treat metastatic prostate cancer include abiraterone, enzalutamide, cabazitaxel, and docetaxel.
The Metastatic Prostate Cancer Drug market is highly competitive, with many companies offering treatments. Some of the major players in the market include Pfizer, Astellas Pharma, Sanofi, Merck, and Johnson & Johnson. Other companies include Bristol-Myers Squibb, Bayer, and Novartis. Show Less Read more
